AzTrials
AzTrials

Advanced CancerPhase 1NCT00955812

STAT3 Inhibitor for Solid Tumors

A Phase 1 study testing OPB-31121 in people with Advanced Cancer and Solid Tumor, run by M.D. Anderson Cancer Center at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with an advanced solid tumor. The safety of this drug will also be studied. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Cancer, Solid Tumor
What is being tested?
OPB-31121
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
2 sitesUnited States
Study dates
Jun 2009to Nov 2012
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects with histologically or radiologically confirmed solid tumors refractory to standard therapy, for which there is no standard therapy, or are not eligible for standard therapy. Subjects must have at least one measurable lesion.
  • Male and female subjects >/= 18 years of age.
  • Male and female subjects who are surgically sterile; female subjects who have been postmenopausal for at least 12 consecutive months; or male and female subjects who agree to remain abstinent or to begin TWO acceptable methods of birth control from one week prior to drug administration through 30 days (for females) and 90 days (for males) from the last dose of study medication. If employing birth control, two of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device (IUD), condom, diaphragm, cervical cap or sponge with spermicide.
  • Eastern Cooperative Oncology Group (ECOG) performance status: </= 2
  • Subjects must have a life expectancy of longer than 3 months.
  • Adequate vital organ function as follows: Neutrophils: >/= 1,500/microliter; platelets: >/= 75,000/microliter; hemoglobin: >/= 9.0 g/dL; Aspartate transaminase (AST), Alanine transaminase (ALT): </= 2.5 * ULN with the exception of subjects with liver metastases. In these cases, AST, ALT </= 5 * ULN for eligibility; serum total bilirubin: < 2.5 * ULN. Subjects must have a normal serum creatinine with a measured 24 hour creatinine clearance of > 60 cc/min; INR < 1.5
Show all 9Show fewer
  • Ability to provide written informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the study.
  • Subjects, who have received prior therapy, eg, chemotherapy, radiotherapy, or surgery, must have stopped therapy for >/= 4 weeks prior to drug administration. Subjects who have received targeted or immunotherapy must have stopped therapy for 5 half lives or 4 weeks prior to drug administration, whichever is earlier, and recovered from any prior toxicity not mentioned above to at least Grade 1.
  • Subjects must have a normal ejection fraction (>/= 50%) as measured by either echocardiogram or multi gated acquisition (MUGA) scan.

Who cannot join

  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Known central nervous system (CNS) metastasis.
  • Presence of active gastrointestinal disease or other condition (eg, significant bowel resections) which has the potential to significantly affect the absorption of the study drug, in the opinion of the investigator or sponsor.
  • Known history of or concurrent hepatitis or acquired immunodeficiency syndrome (AIDS) or known carriers of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies (anti-HCV), or human immunodeficiency virus (HIV) antibodies.
  • Subjects who are pregnant or breast feeding. A negative urine pregnancy test must be confirmed prior to the first dose of study drug for women of child bearing potential (WOCBP).
  • Administration of another investigational agent within 28 days or 5 half-lives for targeted therapy or immunotherapy (whichever is shorter) prior to study entry
  • Use of prohibited medications
  • Subjects with history of coagulopathy (or taking anticoagulants) including deep vein thrombosis (DVT)/pulmonary embolism (PE), myocardial infarction or stroke within the last 6 months.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

  • UT MD Anderson Cancer Center

    Houston, Texas, 77030

  • Sarah Cannon Research Institute (SCRI)

    Nashville, Tennessee, 37203

Other trials in United States

About this study

Official title: A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors

The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with an advanced solid tumor. The safety of this drug will also be studied.

Read the detailed description

The Study Drug:

OPB-31121 is designed to block certain proteins in cancer cells that cause the cancer cells to reproduce and form more cancer cells.

Study Groups:

If you are found to be eligible to take part in this study, you will be assigned to a dose level of OPB-31121 based on when you joined this study. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of OPB-31121 is found.

Study Drug Administration:

On Days 1-21 of each 28-day cycle, you will take the study drug by mouth 2 times a day. You should take the study drug with at least 1 full glass of room temperature, still (non-carbonated) water, within 30 minutes after eating a snack or meal. You should either remain sitting upright or standing for at least 30 minutes after you take the study drug. You will be given directions by the study doctor, the study nurse, and/or the study pharmacist on how to take the study drug at home.

Study Visits:

On Day 1 of Cycle 1, the following tests and procedures will be performed:

  • You will have a physical exam, including measurement of your vital signs.
  • You will have 5 ECGs: 1 before the morning dose of study drug and at 1, 2, 4, and 8 hours after the morning dose.
  • Blood (about 3 tablespoons) will be drawn for routine tests.
  • Your performance status will be recorded.
  • You will be asked about any drugs you may be taking and if you have experienced any side effects.
  • Blood (about 2 teaspoons each time) will be drawn before the morning dose and then 6 more times over the next 12 hours after the dose for pharmacokinetic (PK) testing. PK testing measures the amount of study drug in the body at different time points.
  • Blood (about 2 teaspoons) for pharmacodynamic (PD) testing will be drawn before the morning dose. PD testing is used to look at how the level of study drug in your body may affect the disease.
  • Blood (about 1 teaspoon) will be drawn for pharmacogenomic (PGx) testing. PGx testing looks at how differences in people's genes may affect if and how well the study drug may affect the disease.
  • Women who are able to become pregnant will have a urine pregnancy test.

On Day 2 of Cycle 1, before your morning dose of study drug, the following tests and procedures will be performed:

  • Blood (about 1 teaspoon) will be drawn for a troponin test.
  • Blood (about 4 teaspoons) will be drawn for PK and PD testing.
  • Your performance status will be recorded.
  • You will be asked about any drugs you may be taking and if you have experienced any side effects.

On Days 8, 15, 21, and 28 of Cycle 1, the following tests and procedures will be performed:

  • You will have a physical exam, including measurement of your vital signs.
  • You will have an ECG.
  • Blood (about 3 tablespoons on Days 8 and 15; about 1 tablespoon on Days 21 and 28) and urine will be collected for routine tests.
  • Your performance status will be recorded.
  • You will be asked about any drugs you may be taking and if you have experienced any side effects.

On Day 21 of Cycle 1, blood (about 2 teaspoons each time) will be drawn for PK testing before the morning dose and then 6 more times over the next 12 hours after the dose. Blood (about 2 teaspoons each time) will also be drawn for PD testing.

On Day 22 of Cycle 1, before your morning dose of study drug, the following tests and procedures will be performed:

  • Your performance status will be recorded.
  • You will be asked about any drugs you may be taking and if you had any side effects from them.
  • Blood (about 2 teaspoons) will be drawn for PK testing before your morning dose of the study drug.

On Days 1, 15, and 28 of Cycles 2 and beyond, the following tests and procedures will be performed:

  • You will have a physical exam, including measurement of your weight and vital signs.
  • Your performance status will be recorded.
  • You will be asked about any drugs you may be taking and if you had any side effects from them.
  • You will have an ECG.
  • You will have an echocardiogram or MUGA scan.
  • Blood (about 3 tablespoons) will be drawn for routine tests.
  • You will be asked about any drugs you may be taking and if you have experienced any side effects.
  • Women who are able to become pregnant will have a urine pregnancy test.

About every 8 weeks, you will have an x-ray, CT scan, or MRI scan to check the status of the disease.

Length of Study:

You may continue taking the study drug for as long as you are benefitting. You will be taken off study if the disease gets worse, you experience intolerable side effects, or your doctor thinks that it is no longer in your best interest to receive the study drug.

You may choose to stop taking the study drug at any time. You should tell the study doctor right away if you are thinking about stopping your participation in this study. The study doctor will talk to you about how to safely stop taking the study drug.

End-of-Study Visi:t

Within 14 days after the last dose of study drug, you will return for a final visit. The following tests and procedures will be performed at the final visit:

  • You will have a physical exam, including measurement of your vital signs.
  • You will have an ECG.
  • Blood (about 4 tablespoons) and urine will be collected for routine tests.
  • You will have either an ECHO or MUGA scan.
  • You will have an x-ray, CT scan, or MRI scan to check the status of the disease.
  • Your performance status will be recorded.
  • You will be asked about any drugs you may be taking and if you have experienced any side effects.

Follow-Up:

You will be called about 30 days after the last dose of OPB-31121 and asked if you have experienced any new or ongoing side effects.

This is an investigational study. OPB-31121 is not FDA approved or commercially available. At this time, OPB-31121 is only being used in research.

Up to 36 patients will take part in this multicenter study. Up to 18 will be enrolled at M. D. Anderson.

Being tested
OPB-31121
Keywords
OPB-31121, Advanced Solid Tumor, STAT3, IL-6-induced STAT3 phosphorylation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OPB-31121Drug

    50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.

Study groups in NCT00955812
Study groupRoleWhat they receive
OPB-31121ExperimentalOPB-31121 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
Receives: Drug: OPB-31121

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum Tolerated Dose (MTD) of OPB-31121

    The MTD is defined as the highest dose level at which < 2 of 6 subjects experience dose limiting toxicity (DLT) during the first cycle.

    Measured: 4 Week Cycle

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Aug 2009 (estimated)
  2. Study startJun 2009
  3. Primary completionNov 2012
  4. Study completionNov 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00955812
Sponsor's protocol ID
2009-0206
Status last verified
Feb 2013
First submitted
7 Aug 2009
Last updated
12 Feb 2013
Results posted
No
Data monitoring committee
No

Publications

  • Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):125-30. doi: 10.1007/s00280-014-2480-2. Epub 2014 May 13.

    PubMed 24819685

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing OPB-31121 in people with Advanced Cancer and Solid Tumor, run by M.D. Anderson Cancer Center at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Feb 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Tolerated Dose (MTD) of OPB-31121 (time frame: 4 Week Cycle). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00955812, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2013.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in